Matches in UGent Biblio for { <https://biblio.ugent.be/publication/1036053#aggregation> ?p ?o. }
Showing items 1 to 27 of
27
with 100 items per page.
- aggregation classification "C3".
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2010".
- aggregation hasFormat 1036053.bibtex.
- aggregation hasFormat 1036053.csv.
- aggregation hasFormat 1036053.dc.
- aggregation hasFormat 1036053.didl.
- aggregation hasFormat 1036053.doc.
- aggregation hasFormat 1036053.json.
- aggregation hasFormat 1036053.mets.
- aggregation hasFormat 1036053.mods.
- aggregation hasFormat 1036053.rdf.
- aggregation hasFormat 1036053.ris.
- aggregation hasFormat 1036053.txt.
- aggregation hasFormat 1036053.xls.
- aggregation hasFormat 1036053.yaml.
- aggregation language "eng".
- aggregation subject "Biology and Life Sciences".
- aggregation title "Ovotransferrin, a natural antimicrobial protein against Chlamydophila psittaci in poultry: from the lab to the farm".
- aggregation abstract "Chlamydophila (Cp.) psittaci respiratory infections are highly prevalent in turkeys and the economical and public health importance of these infections has been recognized since 1950. As there are no vaccines, antibiotic treatment is mostly needed to allow marketing of poultry. In this study, we explored the use of ovotransferrin (ovoTF), a natural anti-microbial protein, against chlamydiosis. OvoTF is the avian homologue of lactoferrin. In vitro results demonstrated a direct bactericidal effect of ovoTF on extracellular Cp. psittaci as well as a significant inhibition of chlamydial entry in chicken macrophages (HD11) by blocking the host cell actin polymerization at the bacterial entry site. In a following step, we evaluated the effect of ovoTF in a pre-clinical trial in specific pathogen free turkeys. Turkeys were treated with different ovoTF aerosol doses and administrations regimes prior to the experimental (aerosol) Cp. psittaci (106 TCID50) infection. Birds were monitored during twelve subsequent days. A single dose of 10 mg ovoTF and a repeated (for 12 days) daily dose of 5 mg ovoTF significantly reduced clinical signs, pathology, bacterial excretion and replication in tissues. Next, ovoTF was administered on a turkey broiler farm during two subsequent clinical trials. The influence on Cp. psittaci infection outbreaks as well as on concurrent infections such as Ornithobacterium rhinotracheale (ORT) and the avian metapneumovirus (aMPV) was examined. During the first clinical trial, turkeys received a daily ovoTF aerosol dose of 5 mg per animal, starting at the age of 2 weeks until week 3,5. Aerosol administration was performed by use of an Atomist 1026 spraying device. During the second clinical trial, ovoTF was administered from week 2 until 3,5 and also from week 8 until week 9,5. During clinical trial 1, turkeys were protected against respiratory disease until week 9. No antibiotics were needed until then. At that time, turkeys experienced a Cp. psittaci and ORT infection. During clinical trial 2, ovoTF administration significantly improved the health of the turkeys and no antibiotic treatment was needed. Bioaerosol monitoring for Cp. psittaci showed a positive effect on the infection pressure. Bioaerosol monitoring was performed using the MAS-100 EcoTM Air Sampler and our in-house developed collection medium ChlamyTrap. Cp. psittaci, ORT and aMPV infections still occurred but they were less virulent and passed without clinical manifestations.".
- aggregation authorList BK289570.
- aggregation endPage "149".
- aggregation startPage "149".
- aggregation isDescribedBy 1036053.
- aggregation similarTo LU-1036053.